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Magnetic nanoparticles have beenwidely investigated for their great potential asmediators of heat for localised
hyperthermia therapy. Nanocarriers have also attracted increasing attention due to the possibility of delivering
drugs at speciﬁc locations, therefore limiting systematic eﬀects. The enhancement of the anti-cancer eﬀect of
chemotherapy with application of concurrent hyperthermia was noticed more than thirty years ago. However,
combining magnetic nanoparticles with molecules of drugs in the same nanoformulation has only recently
emerged as a promising tool for the application of hyperthermia with combined chemotherapy in the
treatment of cancer. The main feature of this review is to present the recent advances in the development
of multifunctional therapeutic nanosystems incorporating both magnetic nanoparticles and drugs, and their
superior eﬃcacy in treating cancer compared to either hyperthermia or chemotherapy as standalone
therapies. The principle of magnetic ﬂuid hyperthermia is also presented.ziliz Hervault obtained her
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View Article Online1. Introduction
Nanoparticles (NPs) are dened as particles that have one or
more physical dimensions under 100 nm. Due to their small
size, and particularly due to their increasing surface-to-volume
ratio, the properties of nano-sized materials will diﬀer from the
ones of the bulk material (i.e. optic, catalytic, magnetic and
electronic properties). Thanks to their inherent properties,
magnetic nanoparticles (MNPs) have been developed as
magnetic resonance imaging (MRI) contrast agents,1,2 and
potential new cancer therapies such as magnetic uid hyper-
thermia,3,4 and nanovectors for controlled drug delivery.5,6 NPs
can also be designed to combine several therapeutic functions
(hyperthermia and drug delivery),7,8 or therapeutic and diag-
nostic functions (so-called theranostics).9,10 Scientists have been
attempting to understand the structure and property relation-
ship of NPs to harness their properties.11,12 Indeed, controlling
the composition, size and shape of the NPs via syntheses would
allow tailoring and tuning the desired properties.13–16
Because of their numerous advantages, MNPs and especially
iron oxide NPs, which have been approved by US Food and Drug
Administration, have attracted great interest for their applica-
tions in biomedicine.17 Indeed, iron oxide NPs are relatively easy
to synthesise, biocompatible, non-toxic, chemically rather
stable and can be superparamagnetic. The two main forms of
iron oxide are g-Fe2O3 (maghemite) and Fe3O4 (magnetite). The
phenomenon of local or general rise of the body temperature
above its normal value is known as hyperthermia. It can be used
as a medical treatment, called hyperthermia therapy or ther-
motherapy, in which body tissues are exposed to slightly higher
temperatures in order to damage or kill cancer cells by
provoking cell apoptosis,18,19 or to make cancer cells more
sensitive to the eﬀects of radiation20 and/or certain anti-cancer
drugs.20,21 Apoptosis, also called programmed cell death, is a
distinct mode of cell death, whereby the cells in normal tissues
triggered their self-destruction in response to a signal.19
Contrary to the necrosis, there is no associated inammation.
Apoptosis also occurs spontaneously in cancer cells, thereby
retarding the growth of the tumour, and can be increased when
subjected to heat, irradiation or anti-cancer drugs.
The concept of hyperthermia was already in practice many
centuries ago by Greeks, Egyptians and Romans.22,23 In 3000 BC,
Indian medical practitioners used local and whole body
hyperthermia. During the 19th century, it was observed that
fever can cause tumour regression,23 and scientic study was
performed on hyperthermia to treat cervical cancer.22 The use of
hyperthermia as a treatment for cancer was taken more seri-
ously in the 1970s, and controlled clinical trials on induced
hyperthermia began to be conducted. It was then discovered
that cancer cells have greater sensitivity to hyperthermia as
compared to normal cells. Indeed, healthy tissues are able to
withstand temperatures of 42–45 C, in contrast to cancer cells
which undergo apoptosis at those temperatures.24,25 Treatment
at temperatures above 46 C is called thermo-ablation. It leads
to the necrosis of cancer cells, but may also aﬀect healthy cells.
In contrast to apoptosis that is a natural process, necrosis is a11554 | Nanoscale, 2014, 6, 11553–11573form of cellular damage that results in the premature death of
cells in body tissues and initiates an inammatory response in
the surrounding environment.26,27 It is almost always harmful
and can even be deadly (i.e. can lead to septicaemia or
gangrene). Thus, thermoablation in this temperature range is
not desirable due to the potentially important side eﬀects on
healthy tissues, and hyperthermia induced apoptosis is there-
fore preferable.
While the specic mechanism of cell killing by hyperthermia
is still unknown, the thermal energy needed for induction of cell
death has been found to be close to the energy needed for
protein denaturation, leading to the conclusion that the main
cytotoxic eﬀect of hyperthermia is based on the denaturation of
membrane and cytoplasmic proteins.28,29 Membrane alteration
and cytoskeletal damage such as cell rounding and blebbing
(which is a typical feature of apoptosis) are some of the most
apparent manifestations of thermal damage at the cellular level.
Another important consequence of protein denaturation is the
alteration of DNA synthesis and repair. Higher sensitivity to
heat has been observed for cells in the mitosis phase (with
damage to the mitotic apparatus),28,29 which makes cancer cells
more susceptible to heat than normal cells as they undergo
faster cell division. The tumour selective eﬀect of hyperthermia
is also due to the physiological diﬀerences between normal and
tumour tissues. Indeed, the architecture of the vasculature in
tumour is disorganised and abnormal compared to normal
tissue (one of the principal features being the lower vessel
density). In many cases, tumour blood ow remains greater
than in the surrounding healthy tissues, especially in small
tumours (tumour blood ow generally decreases with
increasing tumour size).30 However, when hyperthermia is
applied at temperatures over 42 C, tumour blood ow tends to
decrease while in normal tissue it signicantly increases. This
decreased blood ow results in a lower heat dissipation rate,
and hence the temperature in a tumour will rise faster than in
normal tissue.30,31 This diﬃculty in dissipating heat may cause
cancer cells to undergo apoptosis, while physiological temper-
atures are more easily maintained in normal tissues.32 The
disorganised structure of tumour vasculature also leads to
oxygen and nutrient deprivation.33 Moreover, regions of
hypoxia, energy deprivation and acidosis are even more fav-
oured with the reduction of the blood ow caused by heat
exposure.28,34 These tumour micro-environmental factors also
make cancer cells more sensitive to hyperthermia,35 in addition
to its direct cytotoxicity.
In fact, hyperthermia may increase or decrease the tumour
oxygenation depending on the temperature and the exposure
time.36 Hyperthermia applied at temperatures lower than 42 C
is more likely to provoke an increase in the tumour blood ow,
thereby improving the oxygen supply. This phenomenon can be
exploited to make cells more sensitive to radiotherapy (radio-
sensitivity is favoured by good tissue oxygenation) or chemo-
therapy (drug delivery is increased by higher perfusion).28,37 The
synergistic eﬀect of hyperthermia with radiotherapy has been
demonstrated in various clinical trials,38,39 and shows better
eﬃcacy than either hyperthermia40 or radiotherapy alone.41 This
synergism induces an increase in cell death even atThis journal is © The Royal Society of Chemistry 2014
Feature Article Nanoscale
O
pe
n 
A
cc
es
s A
rti
cl
e.
 P
ub
lis
he
d 
on
 0
5 
A
ug
us
t 2
01
4.
 D
ow
nl
oa
de
d 
on
 2
5/
01
/2
01
6 
15
:2
6:
31
. 
 
Th
is 
ar
tic
le
 is
 li
ce
ns
ed
 u
nd
er
 a
 C
re
at
iv
e 
Co
m
m
on
s A
ttr
ib
ut
io
n 
3.
0 
U
np
or
te
d 
Li
ce
nc
e.
View Article Onlinetemperatures lower than temperatures normally applied in
hyperthermia therapy. This thermal radiosensitisation is
explained by the increasing blood ow, and by the fact that S-
phase cells (cells undergoing DNA replication) and hypoxic cells
(cells that survive the hypoxia and acidic environment of
tumour), normally resistant to radiation, are highly sensitive to
heat destruction.20,28,42 The synergistic eﬀect of hyperthermia
with chemotherapy has also been demonstrated in clinical
trials.43–45 The increase in blood ow provoked by hyperthermic
treatment results in an increase in drug concentration in the
tumour area, an increase in intracellular drug uptake and
enhanced DNA damage.20 Moreover, heat has been found to
enhance the cytotoxic eﬀect of many anti-neoplastic drugs.21
Consequently, hyperthermia is oen used as an adjuvant
therapy with radio- and/or chemotherapy.37
A wide range of heat sources and treatments for hyper-
thermia are being developed for clinical applications. There are
three main types of hyperthermia: local hyperthermia, regional
hyperthermia and whole-body hyperthermia. The hyperthermia
technique is chosen depending on the location, the depth and
the stage of malignancy. In whole-body hyperthermia, the entire
body is heated up. This method is oen chosen in the case of
deep-seated and propagated metastases. The heating can be
achieved through hot water baths, thermal chambers or infra-
red radiators.46 However, as may be expected, this treatment
may lead to major side eﬀects given the fact that heat is not
selective. Therefore, careful control of the skin temperatures is
needed. Even though temperatures of 41.8–42 C can be ach-
ieved, and the method is clinically realisable, the medical care
needed to ensure a safe procedure in the case of whole-body
hyperthermia is much greater than in local or regional
therapy.37 This has resulted in its limited use as a standalone
procedure. Regional hyperthermia is used to deliver heat to
advanced stage tumours. Thermal perfusion, external applica-
tors or arrays of multiple applicators (microwave antennas) are
example of devices used in regional hyperthermia.46,47 Local
hyperthermia is oen used to treat localised tumours either
supercially or in accessible body cavities. It is the less invasive
technique. Local hyperthermia systems are based on applica-
tors or antennas emitting mostly microwaves, ultrasounds or
radio waves.46,48 Recently, a new technology has been developed
for local hyperthermia using MNPs as mediators of heat. This
technology is called Magnetic Fluid Hyperthermia (MFH).
MFH consists of a colloidal suspension of MNPs which is
injected into the tumour where the MNPs will be internalised by
the cancer cells.49 Applying an external alternative magnetic
eld (AMF) will cause the NPs to heat and kill the cancer cells.
The rst clinical trial was conducted in 2003 on 14 patients
suﬀering from glioblastoma multiform.50 The promising results
led to a phase II study involving 66 patients with glioblastoma
multiforme. Results showed that hyperthermia therapy using
MNPs can be applied safely and is eﬀective for the treatment of
cancer, but also that the overall survival following diagnosis of
rst tumour recurrence is longer compared to conventional
therapies.38 MFH possesses numerous advantages over tradi-
tional techniques. First of all, the injection of MNPs is less
invasive and can be potentially injected and concentratedThis journal is © The Royal Society of Chemistry 2014anywhere in the body, allowing the treatment of all kinds of
tumours with limited side eﬀects. Moreover, once the MNPs
have been internalised into the cancer cells, they are able to
remain inside the cells even aer creation of daughter cells. In
fact, 50% of the amount of MNPs present in parent cells end up
in the daughter cells,51 meaning that a subsequent hyper-
thermic treatment can be applied without large reinjection of
MNPs. Magnetic targeting can be used to drive theMNPs toward
the targeted cancer regions. The MNPs can also be functional-
ised with a recognition moiety (i.e. antibodies, proteins) in
order to increase the selectivity to malignant cells, therefore
increasing the internalisation of the MNPs in the cancer cells.52
The potential of MFH as a treatment for cancer is clear, but can
even be improved by designing MNPs with multiple therapeutic
functions, i.e. hyperthermia and drug delivery. Indeed, drug
delivery by means of NPs also has numerous advantages over
traditional chemotherapy. The major drawback of chemo-
therapy being the non-specicity of the drugs, healthy organs
and cells may also be strongly damaged during the therapy.
With NPs, the possibility of targeting specic locations in the
body allows the reduction of the chemotherapeutic dose to
reach the concentrations needed in the tumour for an eﬀective
therapy. In addition, the concentration of drugs at non-targeted
sites is reduced therefore minimizing undesirable side eﬀects.53
Taking advantage of the synergistic eﬀect of the combined
thermo-chemotherapy, MNP-based therapeutic agents for
hyperthermia and controlled drug delivery are really promising
candidates in the treatment of cancer.
This review aims to demonstrate the great potential of
magnetic nanosystems for the combination of hyperthermia
and chemotherapy, by reporting and discussing promising
examples of the literature. The principle of MFH as well as
recent studies on MNPs for hyperthermia applications is pre-
sented as a basis for understanding the mechanism of magnetic
nanoparticle-mediated hyperthermia therapy.2. Magnetic nanoparticles for
hyperthermia therapy
2.1 Mechanism of heat
The conversion from magnetic energy to thermal energy in
MNPs subjected to an AC magnetic eld can be due to several
mechanisms.
In multi-domain NPs (ferri- or ferromagnetic material), the
production of heat is due to hysteresis losses, which can be seen
as the amount of energy dissipated during a magnetisation
cycle.52,54 A ferromagnet is formed by magnetic domains (Weiss
domains) in which themoments of atoms are all parallel to each
other to maintain a lower energy state, while a ferrimagnet is
formed by magnetic domains with opposing magnetic
moments of diﬀerent amplitudes. When an external magnetic
eld is applied, the magnetic domains tend to align themselves
in the same direction as the applied eld. The saturation
magnetisation is reached as soon as each moment of each
domain is aligned toward this direction. When the applied eld
is removed, the magnetisation does not revert back to zero, andNanoscale, 2014, 6, 11553–11573 | 11555
Fig. 2 Typical curve for a superparamagnetic material (squares show
the orientation of the moment of single-domain nanoparticles with
increasing ﬁeld strength).
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View Article Onlinethis is the remanent magnetisation. In order to reduce the
magnetisation to zero again, a magnetic eld with a precise
intensity needs to be applied, and it is called coercivity (or
coercive eld). The magnetisation curve of a ferromagnet is
represented by a hysteresis loop (Fig. 1) and the hysteresis los-
ses can be measured by integrating the area of the hysteresis
loop.
Superparamagnetism is a form of magnetism that occurs in
ferromagnetic or ferrimagnetic materials, when they are in the
form of suﬃciently small NPs. Indeed, bulk materials basically
contain multiple magnetic domains due to their large size.
However, small enough NPs are single-domain particles, which
can be regarded as one giant magnetic moment composed of all
magnetic moments of the atoms forming the NPs. Super-
paramagnetic NPs are preferred over ferri- and ferromagnetic
NPs for biomedical applications, because they do not retain any
magnetisation once the magnetic eld is removed (Fig. 2).
Single-domain NPs dissipate heat through relaxation losses
which fall in two modes: Ne´el relaxation and Brownian relaxa-
tion. The mechanism of relaxation depends on the size of the
NPs but also on the magnetic material (due to its anisotropy
constant).55 Ne´el relaxation comes from the reorientation of the
magnetic moment in the same direction as the applied
magnetic eld with each eld oscillation.56,57 The Ne´el relaxa-
tion time sN is given by the following equation:
sN ¼ s0 exp

KV
kBT

where s0 ¼ 109 s, K is the anisotropy constant, V is the volume
of the magnetic particle, kB is the Boltzmann constant and T is
the temperature. Ne´el relaxation is strongly size-dependent. A
smaller particle requires less energy for the rotation of its
magnetic moment, consequently the Ne´el relaxation mecha-
nism will be very important.
Brownian relaxation is caused by the friction arising from
the rotation of the particle itself in the carrier liquid.56,57 TheFig. 1 Hysteresis loop of a ferromagnet. The area of the hysteresis
loop represents the energy dissipated during a magnetisation cycle.
11556 | Nanoscale, 2014, 6, 11553–11573Brownian relaxation time sB is expressed by the following
equation:
sB ¼ 3hVH
kBT
where h is the viscosity of the liquid carrier, VH is the hydro-
dynamic volume of the particle, kB is the Boltzmann constant
and T is the temperature. The Brownian relaxation mechanism
is size-dependent too and also strongly viscosity-dependent.58 A
higher viscosity of the liquid medium will slow down the rota-
tion of the particles. Generally, losses by Ne´el relaxation prevail
in small NPs while the Brownian regime dominates in larger
NPs.56,59 In fact, the Brownian losses are not exclusively found in
superparamagnetic NPs.54 For hyperthermia applications, it is
better to have NPs relaxing essentially through the Ne´el mech-
anism, because when internalised in the cells, a change in the
viscosity medium can happen and/or free rotation of the
particles can be prevented.
A combination of the twomagnetic relaxation times gives the
overall eﬀective relaxation time s of the particles:56
s ¼ sBsN
sB þ sN
Application of an AMF oscillating faster than the relaxation
time of the MNPs induces the release of heat from the MNPs
caused by the delay in the relaxation of the magnetic moment.56
The heat dissipation (P) is given by the following equation:60
P ¼ m0c00fH2
where P is the heat dissipation value, m0 is the permeability of
free space, c0 0 is the ACmagnetic susceptibility (imaginary part),
f is the frequency of the applied AC magnetic eld, and H is the
strength of the applied AC magnetic eld.
Quantication of the power dissipation of magnetic nano-
particles in an AMF is usually done by measuring the specic
absorption rate (SAR) expressed in W g1 (also referred to as
specic loss power):56This journal is © The Royal Society of Chemistry 2014
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View Article OnlineSAR ¼ C DT
Dt
where C is the specic heat capacity of the sample and DT/Dt is
the initial slope of the time-dependent heating curve. SAR
highly depends on various parameters such as the size, size
distribution, shape, chemical composition and surface modi-
cation, saturation magnetisation of the particles; and frequency
and amplitude of the applied magnetic eld. A high heating
potential is crucial for the clinical use of MFH, because it would
require a smaller amount of NPs to be injected into the patient.
Therefore, engineering MNPs (control their physical and
chemical properties using synthesis) to obtain an exceptional
SAR value is highly desirable.61–64 For example, most ferri- and
ferromagnetic materials require application of a high magnetic
eld to use a full loop area, which is not realisable clinically due
to physiological and technical restrictions. Therefore, the use of
multi-domain NPs results in low SAR values. On the other hand,
superparamagnetic NPs which produce heat via Ne´el and
Brownian relaxation mechanisms are able to generate a much
larger quantity of heat and thus a higher SAR at lower eld
amplitudes. Hergt et al. suggested that the optimum size to get
particles with a high SAR value is near the transition from
superparamagnetic to ferromagnetic behaviour.65 Considering
the equation of the heat dissipation value, it is clear that SAR
values increase with the frequency f and the eld amplitudeH of
the applied eld. However, in order to apply hyperthermia safely
to patients and avoid any detrimental eﬀect on healthy tissues
due to electromagnetic radiation exposure, the Hf factor should
not exceed a threshold which was experimentally estimated to
equal 5  109 A m1 s1.66
The comparison between SAR values obtained by diﬀerent
research groups can be challenging. Indeed, there is a lack of
standardised protocol to measure the heating ability of the
MNPs. The ideal device for accurate measurement of the SAR
would be an adiabatic setup, but because it is expensive and
time-consuming, most of the research groups use non-adiabatic
and oen home-made setups which results in more sources of
inaccuracies and increased variability of the SAR values.67–69
Also, each research group measures the nanoparticles' heating
capabilities under diﬀerent eld conditions. Indeed, there are
no standards for the frequency and eld amplitude of the
applied eld used during the measurement which makes the
SAR values diﬃcult to compare with each other. Pankhurst et al.
introduced a new parameter able to allow a more direct
comparison of the heating eﬃciency of superparamagnetic
nanoparticles, the intrinsic loss power (ILP).4 The ILP is
obtained by normalizing the SAR by the frequency and eld
amplitude, and is therefore independent of the magnetic eld
parameters.2.2 Nanoparticle delivery to the tumour site
MNPs must be delivered in a secure pathway specically to the
cancer site and should be retained in the tumour in order to
reach a suﬃcient concentration for eﬀective hyperthermia
therapy (as well as for drug delivery). Three main approaches forThis journal is © The Royal Society of Chemistry 2014the delivery of NPs can be distinguished: direct injection,
systematic passive and active delivery.
The direct injection method consists of injecting directly the
magnetic uid into the tumour. The intratumoural injection is
the simplest way to administer the NPs, and is therefore the
most used in in vivo studies70,71 and has even already been used
in clinical trials of MFH.39,72 The main advantage of this tech-
nique is the ease of achieving a high and localised concentra-
tion of MNPs in the tumour. However, the intratumoural
injection of MNPs is only possible in localised and supercial or
easily accessible tumour, thus this approach is limited in the
investigation of many cancers, and particularly advanced stage
cancers. Moreover, direct injection results in a non-homoge-
neous MNP distribution in the tumour, which makes the
complete regression of the tumour diﬃcult.73
Systematic delivery is achieved by injecting MNPs intrave-
nously that will accumulate preferentially in tumour tissue due
to the enhanced permeability and retention (EPR) eﬀect.74,75 The
EPR eﬀect was rst reported by Matsumura and Maeda in
1986,76 and was further investigated and described to a greater
extent by Maeda et al.77–82 The EPR eﬀect rests on the facts that
solid tumours exhibit a defective vascular architecture and that
lymphatic clearance from the interstitium of tumour tissue is
impaired. The former results in an enhanced vascular perme-
ability which facilitates nutrient and oxygen supply to satisfy the
demand of growing tumours, while the latter results in the
retention of macromolecules in the tumour. Therefore, solid
tumours possess a leaky vasculature compared to normal
tissues, which facilitates the extravasation of NPs. Conse-
quently, when NPs are injected intravenously, they can leak out
the blood vessel to deposit in the tumour, and are retained here
for a long time due to impaired lymphatic drainage. MNPs can
also be injected into the artery supplying the blood stream to
the targeted organ in order to improve the deposition of MNPs
in the tumour. To take advantage of the EPR eﬀect, the MNPs
should be able to circulate long enough in the blood stream. For
this purpose, NPs should have a hydrodynamic diameter
smaller than 200 nm to avoid liver clearance and bigger than 50
nm to avoid renal clearance.83 The coating of the NPs can also
play an important role in the permeability and retention of the
NPs in cancer cells, as well as in the blood retention time of the
NPs. In a recent study, superparamagnetic iron oxide NPs were
coated with two diﬀerent polymers for MRI applications: alkali-
treated dextran (ATD) and carboxymethyl dextran (CMD).84 A
muchmore eﬃcient labeling of macrophages was obtained with
the ADT-coated NPs. Aer 4 h, ADT-coated NPs exhibited a
labeling eﬃciency superior to 95% against only 20–30% for the
CMD-coated NPs. Protein adsorption onto the surface of NPs
may accelerate the clearance by the reticulo-endothelial
system53 and aﬀect the bio-reactivity of the NPs.85 An eﬀective
coating can prevent or at least minimize protein attachment
onto the surface of NPs. Finally, NPs have to be stable in the
biological medium to avoid aggregation and conserve the
hydrodynamic size which ensures them a long blood circulation
time. The systematic delivery of NPs via the EPR eﬀect results in
a more global distribution of the MNPs in the tumour compared
to an intratumoural injection, and also permits treating of mostNanoscale, 2014, 6, 11553–11573 | 11557
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View Article Onlineof the types of cancers. However, the principal disadvantage of
this method is the diﬃculty to reach a concentration of NPs
suﬃcient enough for eﬀective treatment, yet the amount of NPs
injected cannot be further increased, in order to avoid non-
negligible MNP toxicity. In order to achieve higher deposition
and improve tumour uptake of the NPs, they can be driven
magnetically inside the body via an external magnetic eld and/
or can be functionalised with a targeting ligand for active
delivery.
Active delivery consists of improving the specicity of the
NPs by functionalising their surface with a targeting moiety that
binds to cell receptors. It usually results in a higher NP accu-
mulation and cellular uptake in the targeted cancer cells.
Among the most commonly used targeting agents, we can nd
antibodies,86,87 antibody fragments,88,89 receptor ligands,90,91
peptides92,93 and aptamers.94,95 The superiority of targeted MNPs
in cancer treatments has already been proven many times. For
example, in a recent study,96 iron oxide NPs were coated with
dextran and functionalised with an anti-human epidermal
growth factor receptor (HER2) aptamer for targeted hyper-
thermia. The results showed that a 90-fold lower dose of the
aptamer-functionalised NPs was necessary to produce a 60%
decrease in the HER2-overexpressing cell viability compared to
the non-tagged NPs. Such an eﬀect was not observed in the
control cell line.
Another targeting system which can be used to improve the
accumulation of MNPs into the tumour site is magnetic tar-
geting, also called magnetophoresis. This technique uses an
external magnetic eld placed near the tumour to magnetically
attract the NPs toward this area. Magnetic targeting has already
shown eﬃciency in in vivo studies.97,982.3 Magnetic nanomaterials for hyperthermia therapy
Numerous materials have been investigated for their potential
use in magnetic hyperthermia, such as Fe, Co, and Ni metallic
NPs and their oxide. Pure metals have the highest saturation
magnetisation, but have limited use in biomedical applications
due to their inherent toxicity and poor chemical stability (quick
oxidation process). Research into metal ferrites has shown good
chemical stability, SAR values and magnetic properties, making
a new class of potential candidates for magnetic hyper-
thermia.61 The eﬀects of Co or Zn dopant on metal ferrite NPs
have also been investigated, showing improved SAR. For
example, 15 nm (Zn0.4Mn0.6)Fe2O4 NPs synthesised by thermal
decomposition exhibit an increased anisotropy and a saturation
magnetisation of 175 emu g1 resulting in a SAR value almost
four times higher than that of Feridex NPs.99 Despite the
superior magnetic properties of metallic NPs, iron oxide NPs are
still the most studied magnetic material for hyperthermia
applications, due to their low toxicity, good biocompatibility,
ease of synthesis and surface functionalisation. The most used
synthetic routes to make iron oxide NPs are the thermal
decomposition of organometallic iron precursors and the co-
precipitation of Fe2+ and Fe3+ aqueous salt in the presence of a
base. The diﬀerent synthetic methods of MNPs for biomedical
applications, including the main parameters (such as the11558 | Nanoscale, 2014, 6, 11553–11573precursor, time and temperature of the reaction, solvent,
ligand, etc.) inuencing the MNP properties, and NP function-
alisation have already been reviewed many times.17,100–103
A number of MNP properties may inuence their hyper-
thermia potential such as the composition, shape, coating,
magnetic properties, size and size distribution. Some recent
studies have been carried out to investigate the inuence of
these properties on the resulted hyperthermia treatment eﬀec-
tiveness, and Kolhatkar et al. recently reviewed parameters that
can be varied to tune the magnetic properties of NPs.104
Carrey et al. recently published a method to identify suitable
or unsuitable materials for hyperthermia.105 A new approach for
the exact calculation of the hysteresis loop is presented and
models for the calculation of the optimum parameters of MNPs
for magnetic hyperthermia, such as the optimum anisotropy,
are provided.
Sedlacik et al. synthesised magnetite NPs by a microwave
irradiation-assisted solvothermal method, using diﬀerent
nucleating agents (ammonium acetate, ammonium carbonate
and aqueous ammonia).106 The highest saturation magnet-
isation was obtained for magnetite NPs nucleated with aqueous
ammonia due to a pure cubic Fe3O4 spinel phase and the
absence of non-magnetic impurities. The lower saturation
magnetisation obtained for the two other NPs was attributed to
the presence of coexisting phases with diﬀerent magnetic
properties, such as goethite. Again, the highest SAR value was
recorded for the NPs nucleated with aqueous ammonia, most
likely caused by their higher saturation magnetisation, their
smaller size and narrow size distribution compared to the
particles obtained with the other nucleating agents. Gonzales-
Weimuller et al. studied the inuence of the size (ranging
from 5 to 14 nm) and polydispersity on the SAR of iron
oxide NPs subjected to an AMF (frequency ¼ 400 kHz; ampli-
tude ¼ 24.5 kA m1).14 The highest SAR value of 447 W g1
(ILP ¼ 1.86 nHm2 kg1) was obtained for the 14 nm NPs.
Moreover, the lower the polydispersity, the higher the SAR value
will be, no matter the NP size. For larger NPs where hysteresis
losses are the main mechanism of heat, the SAR value increases
as the NP size decreases.107 The heating power in MgFe2O4 NPs
was found to be strongly size-dependent, with a SAR maximum
value when the particle size was 10 nm.108 De la Presa et al.
synthesised maghemite NPs of 8 nm, 11 nm, 13 nm and 14 nm
by a co-precipitation method, and studied the inuence of NP
concentration, size, coating, liquid carrier, eld amplitude and
frequency on the SAR value.109 For each NP size, the concen-
tration of NPs dispersed in water does not seem to inuence the
SAR in the studied iron concentration range (6 to 300 mg mL1)
with a eld amplitude of 7.5 kA m1 and a frequency of
522.7 kHz. Increasing the size of the NPs resulted in an
increased SAR value: for 8 nm to 11 nm NPs, the SAR is
increased four times, from 10 W g1 to 40 W g1. For 11 nm to
13 nmNPs, the SAR is only increased from 40W g1 to 55W g1.
Finally, in order to investigate the inuence of the medium
viscosity, the NPs were dispersed in two diﬀerent media, water
and agar. For the smaller NPs, the viscosity has negligible
inuence on SAR values, but for the bigger NPs, the SAR values
drop when they are in the most viscous medium (agar). This isThis journal is © The Royal Society of Chemistry 2014
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View Article Onlinedue to the fact that Ne´el relaxation is mainly responsible for the
production of heat in small NPs, and is not inuenced by the
carrier viscosity. In the bigger NPs, both Ne´el and Brownian
relaxation take part in the heating process. A viscous medium
will slow down the particle rotation, therefore limiting the heat
production mechanism by Brownian relaxation. However,
tissues in the human body can have diﬀerent viscosities. Thus,
it is important to choose NPs with a maximal heating eﬃciency
independent of the media viscosity, meaning that the NPs'
mechanism of heat should be principally by Ne´el relaxation
losses. They concluded that the optimum size for a maximized
viscosity-independent SAR value is around 12 nm for maghe-
mite NPs.
The inuence of the shape on the MNP heating properties
has been less extensively studied than the inuence of the size.
Song et al. synthesised magnetite NPs by thermal decomposi-
tion in octadecene in the presence of oleic acid, and varied the
amount of surfactant and reuxing time to get highly mono-
disperse spherical (9.5 nm) and quasi-cubical (9.6 nm) MNPs.110
The results showed that the quasi cubical MNPs have a higher
SAR value compared to the spherical NPs with an equivalent size
and prepared under the same conditions. This phenomenon
most likely comes from a bigger magnetic core volume of the
quasi cubical MNPs, and higher crystallinity. A huge enhance-
ment of heating performances is observed for multi-core ower-Table 1 Summary of the properties of the magnetic materials describ
parameters
Composition Shape Core size (nm) Coating
Fe3O4 Spherical 5 Pluronic F127
10
12.5
14
g-Fe2O3 Spherical 8 (3-Amino-propyl)triethox
11
13
Fe3O4 Spherical 9.5 2,3-Dimercaptosuccinic
Quasi-cubical 9.6
Fe3O4 Spherical 9 mPEG 2000 Da
mPEG 5000 Da
mPEG 20 000 Da
19 mPEG 2000 Da
mPEG 5000 Da
mPEG 20 000 Da
31 mPEG 2000 Da
mPEG 5000 Da
mPEG 20 000 Da
Fe3O4 Spherical 21.8 —
15.1 Chitosan
g-Fe2O3 Nanoowers 24 Citrate
MgFe2O4 Spherical 7 —
10
13
LSMO Spherical 20 —
30 OA bilayer
LSMO spherical 25 —
Dextran
This journal is © The Royal Society of Chemistry 2014shaped maghemite NPs of 24 nm (constituted of smaller grains
of 11 nm), with a SAR of 1992 W g1.111
MNPs are usually coated with a ligand to improve their
biocompatibility and their colloidal stability, because NP
aggregation would modify the NP properties (and therefore
their heating properties), and once injected into the body, it
would probably result in the clearance of the MNPs by the
reticulo-endothelial system before they could reach the
desired location. The choice of the ligand is important
because it can modify the magnetic properties of the NPs. For
example, Larumbe et al. showed that silica coating on
magnetite NPs resulted in a decrease of the magnetic prop-
erties and the SAR value, due to an enhancement of the spin
disorder surface eﬀects caused by the silica coating.112 Thus,
the surface coating needs to be optimised to get the best
hyperthermic agents. In a recent study, magnetite NPs with
controlled particle size (9 nm, 19 nm and 31 nm) and mPEG
surface coating thickness (by varying the molecular weight:
2000 Da, 5000 Da, and 20000 Da) were synthesised by thermal
decomposition.64 The heating eﬃciency was observed to
decrease with increasing polymer chain length, except for the
biggest NPs. Indeed, the 31 nm NPs coated with 2000 Da
mPEG agglomerates, which means that the polymer has too
short chains to provide good colloidal stability due to a
strong magnetic dipole–dipole interaction. Similar behav-
iour is observed for the measured SAR values. The highested in Section 2.3 with their corresponding SAR, ILP values and AMF
H (kA m1) f (kHz) SAR (W g1) ILP (nHm2 kg1) Ref.
24.5 400 180 0.75 14
130 0.54
200 0.83
447 1.86
ysilane 7.5 522.3 10 0.34 109
40 1.36
55 1.87
acid 30 100 29 0.32 110
35.1 0.39
27 400 367 1.26 64
332 1.14
267 0.92
930 3.19
686 2.35
535 1.83
355 1.22
883 3.03
565 1.94
26.7 265 79.32 0.42 113
118.85 0.63
21.5 700 1992 6.16 111
8 279 13.4 0.75 108
19 1.06
10.2 0.57
26.7 267 27 0.14 114
40.22 0.21
26.7 265 27 0.14 115
51 0.27
Nanoscale, 2014, 6, 11553–11573 | 11559
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View Article OnlineSAR value achieved was 930 W g1 for the 19 nm NPs coated
with 2000 Da mPEG and the lowest was 267 W g1 for the 9
nm NPs coated with 20000 Da mPEG. Therefore, these results
show that the SAR can be signicantly improved by opti-
mizing the surface coating and the magnetic core size. The
eﬀect of chitosan coating on magnetite NPs has also been
studied recently, showing an improved SAR compared to bare
magnetite NPs.113 A bilayer of oleic acid has been shown to
improve the hyperthermia properties of La0.7Sr0.3MnO3
(LSMO) NPs,114 arising from an improved colloidal stability of
the NP suspension at physiological pH. This study also shows
the eﬀect of ionic strength on the heating eﬃciency of the
NPs. A drop of the SAR is observed due to decreasing colloidal
stability when NaCl is added to the NP suspension (the
higher the NaCl concentration, the lower the SAR). A dextran
coating also enhances the hyperthermia potential of LSMO
NPs.115 It is believed to be due to the ability of the dextran
coating to retain the superparamagnetic fraction of the LSMO
NPs and the improved colloidal stability of the coated NPs.
A summary of the main parameters, including SAR and ILP
values of the magnetic materials described in the Section 2.3, is
given in Table 1. Heating eﬃciencies of commercially available
ferrouids have been studied and tabulated elsewhere.4
It is important to control the temperature during magnetic
hyperthermia treatment, in order to avoid overheating of the
surrounding healthy tissues. However, precise control of the
temperature can be diﬃcult to achieve, and therefore, magnetic
materials with a maximum self-heating temperature are very
attractive for hyperthermia applications. The Curie temperature
(Tc) is an intrinsic property of magnetic materials. Above this
temperature, the magnetic system becomes paramagnetic
(Fig. 3) and therefore heating stops.
By choosing a material with a Tc close to the hyperthermia
temperature range and adjusting it to the desired therapeutic
temperature (the Tc of a magnetic system can be modied to a
certain extent with the chemical composition), the heating of
the tumour can be controlled and the temperature can be
maintained at a constant desired value for self-controlled
hyperthermia treatment. For example, the Tc of Mn-ferrites
can be decreased by replacing magnetic ions with non
magnetic Ti4+ ions (Mn1+xTixFe2O4), from 300 C at x ¼ 0 to
about 35 C at x ¼ 0.6.116 A Tc of 46 C was obtained at
x ¼ 0.55. Among the magnetic materials with a tunable Tc in
the therapeutic temperature range, we can nd:Fig. 3 Schematic representation of the moments of atoms of a
ferromagnet below and above its Curie temperature in the absence of
an applied magnetic ﬁeld.
11560 | Nanoscale, 2014, 6, 11553–11573La1xSrxMnO3 whose Tc increases with an increasing Sr
content,117 Gd-substituted Zn-ferrite (ZnGdxFe2xO4) whose
Tc increases with an increasing Gd content and was found
around 45 C at x ¼ 0.02,118 Ni1xCrx whose Tc increases with
a decreasing Cr content and was found equal to 44 C at
x ¼ 5.63,119 and Mg1+xFe22xTixO4 whose Tc decreases with a
decreasing Fe content and was found around 46 C for
x ¼ 0.37.1202.4 Examples of in vivo application hyperthermia therapy
Monocyte/macrophage-like cells (Mo/Ma) are tumour-
homing cells. They are known to inltrate tumour sites and
have been shown to specically accumulate in pancreatic
tumours when injected intraperitoneally. Basel et al. used
Mo/Ma cells to carry core/shell iron/iron oxide NPs directly
into the tumour of C57BL/6 mice injected with Pan02 cells to
generate a murine model of disseminated pancreatic
cancer.121 The Mo/Ma cells loaded with MNPs were therefore
injected intraperitoneally, and three days aer the injection,
the mice were subjected to 20 min of AMF exposure. The mice
subjected to the hyperthermia treatment survived signi-
cantly longer than the other mice in AMF, Mo/Ma cells or
MNPs control groups, with a 31% increase in lifespan.
Lin et al. used Mn–Zn ferrite NPs coated with poly-
ethyleneimine to evaluate the anti-cancer eﬀects of the
magnetic uid with and without combined radiotherapy in
vitro and in vivo.122 They chose a magnetic uid with a NP
concentration of 10 g L1 because it stabilised around 43 C
under application of an AMF of frequency ¼ 230 kHz and
amplitude ¼ 1 kA m1. Tumours were grown into the right
posterior limb rump of nude mice by injecting exponentially
growing HepG2 cells. The magnetic uid was injected intra-
tumourally following a multipoint injection strategy, and the
hyperthermic treatment was applied for 1 h. The volume
inhibition rate and mass inhibition rate of the combined
group were 87.62% and 88.62%, respectively, against 41.04%
and 34.20% for the radiation-alone group and 79.87% and
77.92% for the hyperthermia-alone group. The in vivo
experiments revealed good inhibition of the tumour growth,
for both hyperthermia alone and the combined treatment.
Ferucarbotran (also called Resovist) consists of clinically
approved superparamagnetic iron oxide nanoparticles (SPIONs)
coated with carboxydextran developed for contrast-enhanced
MRI of the liver. Those NPs can also be used for hyperthermia
therapy as they are able to generate heat when subjected to an
AMF. Araya et al. injected A549 cells (non small cell lung cancer
cell line) in BALB/c nu/nu athymic female nude mice and
studied the anti-cancer eﬀects of ferucarbotran-mediated
hyperthermia.123 Ferucarbotran NPs were injected intra-
tumourally and the temperature was maintained at 43–45 C
for 20 min by application of an AMF. Even when complete
tumour suppression was not fully achieved, the tumour volume
was signicantly suppressed.
Some clinical trials have been performed on MNPs for
hyperthermia therapy and have been summarized by Thiesen
& Jordan in 200850 and by Zhao et al. in 2013.124This journal is © The Royal Society of Chemistry 2014
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View Article Online3. Magnetic nanosystems for thermo-
chemotherapy
3.1 Enhancement eﬀect of the combined therapy
The enhancement of chemotherapy eﬀects with application of
concurrent hyperthermia is called thermo-chemosensitisation.
Several mechanisms are involved in this thermal enhancement,
such as increased antineoplastic drug accumulation in tumours
and enhanced drug cytotoxicity (improved intracellular uptake
of drugs and increased sensitivity of cells to drugs).125,126 The
rst one is due to the physiological eﬀect of mild hyperthermia
on tumour vasculature, including an increased blood ow,
perfusion, and blood vessel pore size of the already leaky
tumour vasculature. All these factors facilitate drug extravasa-
tion in tumour tissues. The mechanisms responsible for the
enhanced drug cytotoxicity are not yet fully understood, but
generally involve improved intracellular uptake of drugs due to
increased cell membrane permeability, inhibition of DNA-
repair of the chemically induced lethal or sublethal damage,
and acceleration of the cytotoxic chemical reaction in the case
of alkylating or platinum-based antineoplastic agents at
elevated temperatures.21 Fig. 4 summarizes the mechanisms
behind the synergistic eﬀect of hyperthermia and
chemotherapy.
Several studies have demonstrated that the thermal
enhancement of the cytotoxic activity of many anti-cancer
agents is maximized at mild hyperthermia temperatures (40.5–
43 C).127 Chemotherapeutic drugs can be classied into four
diﬀerent categories depending on the way heat aﬀects their
cytotoxicity:128
- Agents exhibiting a linear increase in cytotoxicity with
increasing temperature: alkylating antineoplastic drugs
(nitrogen mustards, nitrosoureas and thiothepa), platinum-
based chemotherapeutic drugs (i.e. cisplatin), mitorantrone
and mitomycin C are part of this category.
- Agents showing a threshold temperature eﬀect: they do not
undergo a linear increase but only a little change in cytotoxicity
with increasing temperatures until a threshold of 42–43 C.
Above this threshold, a synergetic eﬀect is observed. This is the
case of adriamycin, bleomycin and actinomycin D.Fig. 4 Mechanisms responsible for the synergistic eﬀect of the
combined therapy.
This journal is © The Royal Society of Chemistry 2014- Agents not presenting any change in cytotoxicity with
higher temperatures: antimetabolites, methoterate, 5-uoro-
uracil, amsacrine, and vinca alkaloids (vincristine and vinblas-
tine) show temperature-independent action.
- Agents that are not cytotoxic at 37 C, but become cytotoxic
with increasing temperatures. This type of cytotoxicity is char-
acteristic of cysteamine, amphotericin B and lidocaine.
Diﬀerent studies have aimed at evaluating the thermal
enhancement of the cytotoxic activity of some chemothera-
peutic drugs as well as the mechanisms behind. The thermal
enhancement of cisplatin and adriamycin cytotoxicity was
evaluated in vitro using a human bladder cancer cell line.129
Mild hyperthermia alone (41 C) and low drug concentration (20
mg mL1 of cisplatin or 4 mg mL1 of adriamycin) did not have
any cell killing eﬀect. However, the anti-tumour eﬀect of the
combined therapy was signicantly higher than either hyper-
thermia or drug alone, using the same drug concentrations and
hyperthermia temperature. Indeed, the survival rate in the case
of the combined treatment was the same as that of a 10-fold
higher concentration of cisplatin or adriamycin administered
alone. These results indicate that the quantity of drugs used in
chemotherapy for the treatment of cancer can be eﬀectively
reduced by combination with mild hyperthermia, thereby
limiting the side eﬀects of the treatment. The mechanisms of
action of the two drugs are the following: cisplatin interacts
with DNA to form DNA intrastrand crosslink adducts (DNA
platination).130 Crosslinks cause DNA replication arrest and
apoptotic cell death if they are not repaired. Cisplatin therefore
inhibits DNA synthesis and cell division. Adriamycin interca-
lates into DNA and inhibits the enzyme topoisomerase II
resulting in DNA damage and cell death. Adriamycin can also
generate free radicals (reactive oxygen species) which damage
the cellular membrane, DNA, and proteins and lead to apoptotic
cell death.131 Mechanisms responsible for the thermal cytotox-
icity enhancement of both drugs are most likely due to an
increase of cellular uptake, therefore DNA damage and possibly
inhibition of DNA repair.
Onconase is a cytotoxic ribonuclease which binds to cell
surface receptors, degrades ribosomal RNA once internalised to
the cell and inhibits protein synthesis causing apoptotic cell
death.132,133 Onconase also suppresses proliferation, is cytotoxic
to several tumour cell lines and is synergistic with many anti-
cancer agents. The thermal enhancement of the onconase
cytotoxic eﬀect by mild hyperthermia was evaluated in vitro on
human lymphoblastoid TK6 cells. The percentage of apoptotic
cells was measured aer treatment with onconase alone (2 or 5
mg mL1), hyperthermia alone (40 C or 41 C), for a treatment
duration of 24 h or 48 h, and for the combined treatment. The
results are presented in Table 2.
The increased therapeutic eﬀect of mild hyperthermia with
onconase was observed at 41 C and even at 40 C, the
temperatures at which the cells were not aﬀected at all. The
thermal enhancement mechanism of onconase cytotoxic
activity is not known with certainty. However, it is believed that
an increase in intracellular uptake of the drug and accelerated
kinetics of ribosomal RNA degradation is responsible for the
synergistic eﬀect of the therapy.Nanoscale, 2014, 6, 11553–11573 | 11561
Table 2 Percentage of apoptotic cells after 24 h and 48 h of treatment
Treatment
duration
Onconase
concentration
Temperature
37.5 C 40 C 41 C
24 h 0 mg mL1 6% 6% 25%
2 mg mL1 13% 39% >50%
5 mg mL1 15% 49% >55%
48 h 0 mg mL1 — 7% 45%
2 mg mL1 33% 54% 74%
5 mg mL1 42% 77% 85%
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View Article OnlineThe thermal enhancement of melphalan (alkylating agent)
and oxaliplatin (platinum-based agent) cytotoxicity was studied
in vitro using spontaneous brosarcoma FSa-II tumour cells, as
a function of treatment time at temperatures between 37 and
44.5 C with a constant concentration of melphalan (0.25 mg
mL1) or oxaliplatin (7.5 mg mL1).134 For both drugs, a thermal
enhancement was observed (more pronounced in the case of
melphalan) which became greater with increasing temperatures
or increasing treatment time. The mechanism of the eﬀect of
oxaliplatin has been found to be the same as that of cisplatin
(formation of DNA intrastrand crosslink adducts which inhibits
DNA replication and leads to cell death). Melphalan interacts
with DNA to form interstrand crosslink adducts, also causing
apoptotic cell death. At physiological temperatures, they
observed a constant cell killing eﬀect indicating that cytotoxic
reactions occurred at a constant rate. With increasing temper-
atures, the reaction rate became faster. Thus, at mild hyper-
thermia temperatures (below 42 C), the mechanisms
responsible for the thermal enhancement of the drug cytotoxic
activity seem to be mostly an increased rate of chemical reac-
tions leading to cell death, the inhibition of DNA repair of drug-
induced DNA damage and an enhanced intracellular uptake of
drugs. Above 42 C, hyperthermia has a direct killing eﬀect on
cells due to the denaturation of proteins induced by heat. This
study also highlights the importance of the thermal dose: the
heating temperature and the time of exposure greatly inuence
the interaction between heat and drug.
Other numerous studies showed a thermal enhancement of
drug cytotoxicity. For example, the combined treatment of
hyperthermia at 43 C for 45 min and cisplatin or etoposide
resulted in more apoptotic cells than hyperthermia or drug
alone with a lower concentration of the drug.135 Again with
cisplatin, the combined treatment was 1.7 times more eﬀective
than hyperthermia alone (43 C, 60 min) and 1.4 times more
eﬀective than cisplatin alone.136 Hyperthermia was in this case
applied by means of iron oxide NPs. BCNU (1,3-bis(2-chlor-
oethyl)-1-nitrosourea), an alkylating agent, causes DNA inter-
strand crosslinks which lead to cell death. The alkylation
reaction rate is accelerated by hyperthermia which results in an
increased cell death.137 A comparative study of some of the
clinically employed platinum-based anticancer agents
(cisplatin, carboplatin and oxaliplatin) demonstrates a cytotoxic
thermal enhancement for all of them.138 However, a true
synergistic eﬀect was observed in the case of cisplatin, while11562 | Nanoscale, 2014, 6, 11553–11573only an additive eﬀect was reported for carboplatin and oxali-
platin. All these studies reveal that the most eﬀective treatment
is achieved when hyperthermia and the drug are administered
simultaneously, but some exceptions exist. Thus, drug phar-
macokinetics has to be investigated to be able to benet as
much as possible from the improved anti-cancer eﬀect of the
treatment using a minimum amount of drugs thereby mini-
mizing the toxicity. For instance, gemcitabine needs a time
interval of 24 h between drug administration and application of
hyperthermia to obtain a synergistic eﬀect.21
There is a concern about the oncogenic potential of many
anti-cancer drugs. Hyperthermia combined with chemotherapy
has the potential to reduce the risk of treatment-induced
secondary cancer because hyperthermia seems to lower onco-
genic transformations. Indeed, hyperthermia converts suble-
thal damage induced by the drug to lethal damage and/or
inhibits DNA repair, therefore reducing the expression of
transformation. Moreover, cells in S-phase are particularly
sensitive to heat, and transformation mainly occurred when
cells are in S-phase. Thus, hyperthermia could reduce the
frequency of transformation induced by chemotherapy. A study
dedicated to the oncogenic potential of hyperthermia combined
with either actinomycin D, mitomycin C or carmustine showed
a reduction of the drug-induced transformation for a given level
of cell killing compared to the administration of the drug
alone.139 A reduction of oncogenic transformations was also
reported in the case of melphalan140 and cis-platinum.140,1413.2 Nanosystems for simultaneous hyperthermia and drug
release
Anti-cancer agents are highly cytotoxic for both cancer and
healthy tissues. The controlled release of drugs in a localised,
targeted area is an important stake in chemotherapy, as it would
allow the reduction of systematic exposure therefore mini-
mizing the side eﬀects, and also the reduction of the amount of
drug used during the therapy. This becomes possible using
nanosystems as a vehicle for drug delivery.9,142–146 The chemo-
therapeutic drug is stored and protected in the nanocarrier
until it reaches the cancer site, where it is released. The drug is
thus harmless to healthy tissues during its circulation in the
body, and provided in high concentrations at the desired
location.
Diﬀerent nanoformulations incorporating both MNPs and
drugs have been created for the purpose of thermo-chemo-
therapy. A growing area in drug and gene delivery is the use of
stimuli-responsive compounds, and especially thermo-sensitive
polymers, to trigger the release of drugs.147 The use of MNPs for
local hyperthermia is therefore particularly relevant to this
purpose. Indeed, the heat produced by the MNPs under appli-
cation of an AMF will trigger the fast release of the drug, and
increase the eﬀectiveness of the treatment due to the synergistic
eﬀect of the simultaneous application of hyperthermia and
chemotherapy. The incorporation of MNPs also oﬀers the
possibility of guiding the magnetic nanosystems in the body to
target the tumour by the application of a static external
magnetic eld.This journal is © The Royal Society of Chemistry 2014
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View Article OnlineStimuli-responsive polymers, also called smart polymers,
have the ability to change properties in response to a change in
their environment such as the temperature, pH, light, magnetic
eld, etc.148 Thermo-responsive polymers respond to tempera-
ture: they undergo a conformational change at a specic
temperature, called the lower critical solution temperature
(LCST). Below the LCST, the polymer is in a swollen hydrophilic
state and transform to a shrunken hydrophobic state above the
LCST by expelling the aqueous content. The most studied
polymer for thermo-responsive drug delivery systems is poly(N-
isopropylacrylamide) (PNIPAAm) which has a LCST of 32 C in
water. By varying the ratio of the hydrophilic/hydrophobic co-
monomer, the LCST of a given polymer can be tuned.149 This
behaviour is therefore used to remotely trigger the release of the
drug: by tuning the LCST to be in the hyperthermia temperature
range, the drug will be retained at physiological temperature,
and release as a consequence of hyperthermia. pH-responsive
polymers are also oen exploited for drug delivery applications
because of the pH changes found in the human body. The pH in
the tumour environment is oenmore acidic than the pH in the
blood or healthy tissue. pH-sensitive drug delivery systems can
target the tumour site and release their payload due to the pH
diﬀerence.
The approach of simultaneous thermo-chemotherapy using
magnetic nanosystems is relatively new. Kumar and Moham-
mad recently reviewed and proposed extending the meaning of
the term hyperthermia to cover both hyperthermia therapy and
magnetically modulated controlled drug delivery through
heating.150 In this case, heat is only used as a trigger for drug
release. In our context, hyperthermia and chemotherapy ther-
apeutic functions are combined in the same nanosystem taking
advantage of the great potential of MFH and controlled drugFig. 5 Important nanosystems for application in thermo-chemotherapy
This journal is © The Royal Society of Chemistry 2014delivery in the treatment of cancer, and also beneting from the
synergetic eﬀect of the combined therapy. The most relevant
organic/inorganic designs developed so far will be presented,
focusing on themost encouraging results of pH- and/or thermo-
sensitive systems for the triggerable delivery of drugs under
application of an external AMF. Among them, we can nd core/
shell NPs, liposomes, micelles, and polymeric carriers such as
hydrogels or polymeric NPs. Figure 5 displays the most impor-
tant biologically useful nanosystems for simultaneous thermo-
chemotherapy, which are usually administered intratumourally
or intravenously.3.3 Diﬀerent nanosystem designs
3.3.1 Liposomes. Liposomes are spherical vesicles
composed of an aqueous core surrounded by a lipid bilayer.
Liposomes are one class of the most attractive and studied
systems for drug delivery. Hydrophilic chemotherapeutic drugs
can be entrapped in the aqueous compartment, while hydro-
phobic drugs can be encapsulated in the lipid membrane.
Liposomes change the pharmacokinetics of the drug and lower
its systematic delivery and toxicity. With the major advance-
ment of long circulation liposomes (by incorporating PEG-
chains in the lipid bilayer),151 liposomal formulation is now able
to increase the circulation time of the drug in the body (avoiding
clearance by the reticuloendothelial system and renal ltration),
and enhance the drug deposition in the tumour via the EPR
eﬀect.
Magnetoliposomes are formed by incorporating magnetic
nanoparticles into the liposome with the molecules of the drug,
either in the core for NPs stable in aqueous solution152 or in the
lipid membrane for NPs in a hydrophobic state.153 Temperature-
sensitive liposomes use specic lipid and polymers to achieve.
Nanoscale, 2014, 6, 11553–11573 | 11563
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View Article Onlinetemperature-sensitive release of drugs. Under the phase tran-
sition temperature of the bilayer, drugs are retained inside the
liposome, until they are released in tumour tissue or vascula-
ture as a consequence of heat causing bilayer disruption. As
thermo-sensitive liposomes have been widely investigated for
drug delivery, we refer the reader to several well-documented
reviews on the subject.154–156 Thermo-sensitive magneto-
liposomes have shown potential eﬃcacy for the combined
treatment of cancer. For example, liposomes with MNPs
encapsulated in the lipid bilayer and calcein (as a model of
hydrophilic drug) loaded into the aqueous compartment have
shown interesting “on-demand” release properties.157 The
release can be triggered repetitively, by switching ON and OFF
the AMF, with almost inexistent cargo release when the AMF is
turned OFF. This property is due to the reversible permeability
change of the lipid bilayer rather than the destruction of the
liposome, and is really interesting to control dose, location and
time of drug release, with simultaneous magnetic nano-
particles' hyperthermia.
Kulshrestha et al. developed paclitaxel loaded magneto-
liposomes and achieved a better cell killing eﬃcacy than mag-
netoliposomes or paclitaxel loaded liposomes alone.158 The
liposome lipid bilayer was formed from 1,2-dipalmitoyl-sn-
glycero-3-phosphocholine (DPPC) and 1-palmitoyl-2-oleoyl-sn-
glycero-3-phospho-rac-glycerol (PG) (9 : 1, w/w). The transition
temperature of DPPC is 41 C, while the one of PG is 1 C.
However, adding a small amount of PG proteins to the DPPC
lipid bilayer has shown to increase the stability of the bilayer,
without lowering too much the transition temperature and
thereby minimizing the release of the drug at temperatures
lower than the transition temperature. Magnetite NPs coated
with citric acid and paclitaxel were successfully encapsulated
(83  3% and 74.6  5%, respectively) into the liposome
aqueous compartment. The drug release behaviour was studied
under an AC magnetic eld at 37 C and 43 C. At 37 C, only
1.2% of paclitaxel were released compared to 55.6% at 43 C.
The in vitro experiments were performed on HeLa cells, and
hyperthermia was applied at 42.5  1 C for a duration of 30
min with magnetoliposomes containing 6 mg mL1 of MNPs
only or in combination with 100 nM paclitaxel. The cell viability
was decreased by 37% aer the heat treatment alone and by
about 50% for paclitaxel loaded magnetoliposomes without
application of an AMF, while the combined treatment resulted
in 89% cell killing. Thus, this liposomal formulation shows
promising potential for cancer thermo-chemotherapy, because
of its good biocompatibility, the slow drug release at 37 C, the
magnetic nanoparticles' hyperthermia-triggered burst drug
release and the synergistic eﬀect of the combined treatment.
3.3.2 Micelles. Surfactants are composed of a hydrophilic
head group and a hydrophobic tail. When in aqueous solution,
they spontaneously assemble into an aggregate with the polar
heads facing the surrounding water and a hydrophobic, water-
excluding core. Hydrophobic drugs can therefore be encapsu-
lated into the micelle core. Drug molecules can even be directly
conjugated to the polymer structure via a cleavable link.159 As
liposomes, micelles extend the circulation time of the drugs in
the body, enhance their accumulation via the EPR eﬀect in the11564 | Nanoscale, 2014, 6, 11553–11573tumour and protect them against renal and reticuloendothelial
clearance. Micelles can be engineered to be thermo-responsive
via incorporation of a thermally sensitive polymer either in the
head polar group or the non-polar tail. Micelles have been
widely used as drug delivery systems, and several recent good
reviews can be found on the subject of polymeric micelles.159–161
Micelles with a thermo-sensitive corona are usually used for
drug delivery applications. The thermo-sensitive polymer
undergoes a conformational change from hydrophilic state to
hydrophobic state when it reaches its LCST, therefore destabi-
lizing the micelle structure and allowing the release of the drug.
The collapse hydrophobic corona may interact with the cellular
membrane resulting in enhanced intracellular uptake.162 The
micelles can be loaded with MNPs and drug at the same time to
form magnetic micelles that can be used for hyperthermia with
combined chemotherapy.
Kim et al. investigated the potential of thermo-sensitive
magnetic micelles for concurrent hyperthermia and drug
release: poly(N-isopropylacrylamide-co-acrylamide)-block-pol-
y(3-caprolactone) (P(NIPAAm-co-AAm)-b-PCL) random block
copolymer micelles (70 nm) were loaded with magnetite SPIONs
(11 nm).163 P(NIPAAm-co-AAm)-b-PCL is amphiphilic and PCL
forms the hydrophobic tail and will therefore comprise the core
of the micelle. The LCST of the micelles was estimated to be
43 C, but the PCL soening starts at 40 C. The magnetic
micelles were prepared with diﬀerent weight ratios (1 : 0, 1 : 0.2,
1 : 0.5, 1 : 1, 1 : 2, 1 : 3, 1 : 4, and 1 : 5) of P(NIPAAm-co-AAm)-b-
PCL and SPIONs and loaded with doxorubicin (DOX) with a 66%
drug-loading eﬃciency. It appears that only the weight ratios
from 1 : 1 to 1 : 3 gives stable micelle structures. The drug
release abilities by heating the micelles (with a 1 : 1 weight ratio
of polymer to SPION) via a water bath or magnetic heating were
compared. At physiological temperature, the release of DOX was
not signicant. The amount of DOX released at 43 C is at least
three times higher when the micelles were subjected to an AMF
than heated with a water bath which is due to the direct thermal
energy transfer from the SPIONs to the lipid layer. The trigger
drug release at 43 C (LCST) is due to the dehydration of the
polymer outer shell and the relaxation of the PCL core resulting
in the shrinkage of the micelle and the expulsion of the drug
molecules. This micelle formulation could therefore be
employed for the combination of thermo-chemotherapy.
3.3.3 Polymeric nanoformulations. In this section,
magnetic NPs encapsulated in either polymeric NPs or hydro-
gels will be detailed.
Polymeric nanoparticles are of great interest for biomedical
applications due to the possibility of controlling and tuning
their compositions, structures and properties (i.e. shape, size,
surface charge, functionalisation) due to a controlled reaction
of polymerisation.164 Several MNPs and drug molecules can be
encapsulated in the same polymeric NP, to be used as agents for
thermo-chemotherapy. From the choice of the polymers
comprising the NPs as well as the diﬀerent polymer ratios, new
or improved properties can arise, such as thermo-sensitivity,
biocompatibility, etc.
An interesting study developed a pH- and temperature-
sensitive nanosystem composed of 10 nm SPIONs and two anti-This journal is © The Royal Society of Chemistry 2014
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View Article Onlinecancer drugs encapsulated in a poly(D,L-lactic-co-glycolic acid)
(PLGA) shell for the combined therapy.165 The anti-cancer
agents, curcumin and 5-uorouracil (5FU), were loaded with a
71% and 63% eﬃciency, respectively. Curcumin causes a
decrease in the mitochondrial membrane potential while 5FU
inhibits the synthesis of DNA and RNA. Finally, the NPs were
functionalised with folate (its receptors are highly displayed in
several carcinomas) and transferrin (transferrin receptors are
highly overexpressed in cancer cells) to obtain dual targeted,
dual drug loaded MNP-encapsulated PLGA nanovectors (150
nm). The drug release percentage was found higher for both
drugs under acidic pH, and reached more than 70% in the case
of curcumin and 80% in the case of 5FU aer about 80 h. Three
diﬀerent cell lines were used for the in vitro studies: a human
breast cancer cell line (MCF7 cells), a human glial cell line (G1
cells) and a mouse broblast cell line (L929 cells, control cells).
The better targeting eﬃcacy of the dual-targeted NPs (higher
specicity and uptake than single-targeted NPs) was clearly
evidenced by the internalisation studies and cytotoxicity assays.
The latter also demonstrated the synergistic eﬀect of using
curcumin and 5FU together, therefore resulting in an enhanced
therapeutic eﬀect compared to the use of a single drug. The
eﬀects of simultaneous drug release and magnetic hyper-
thermia (frequency ¼ 305 kHz; amplitude ¼ 18.3 kA m1) were
evaluated aer 60 and 120 min of treatment. The use of non-
targeted NPs resulted in a high reduction of the cell viability for
both healthy and cancer cells, due to the lack of specicity of the
nanovector. In contrast, treatment performed with the dual-
targeted NPs shows a radical cytotoxic eﬀect on cancer cells,
without really damaging the healthy cells. Thanks to the dual
targeting ability, both heat and drugs are targeted to cancerous
tissue. The cell viability aer 60 min and 120 min of treatment
was 41% and 28% for the MCF7 cells, and 38% and 26% for the
G1 cells, respectively. Even aer removal of the AMF, the cell
viability continues to decrease. 12 h aer the hyperthermic
treatment, the cell viability was 16% and 11% for MCF7 and G1
cells, respectively, while 24 h aer, the cell viability was reduced
to 7% and 4% for MCF7 and G1 cells, respectively, which clearly
demonstrates the synergistic eﬀect of the combined treatment.
In another recent study, the authors chose to use Mn–Zn
ferrite NPs for their Tc close to body temperature and adjustable
(by varying the ratio of Zn2+ to Mn2+), which enables the control
of the maximum heating temperature reached during the
hyperthermia experiment.166 Mn0:2Zn0:8Fe2O4 NPs (7 nm) were
encapsulated in a thermo-sensitive copolymer composed of
N-isopropylacrylamide (NIPAAm) and N-hydroxymethylacrylamide
(HMAAm). A 7 : 1 PNIPAAm/HMAAmmolar ratio was selected, as
it was found that its LCST was equal to 40.1 C. The polymeric
NPs were loaded with 10%, 8% and 6% of MNPs and subjected
to an AMF (frequency¼ 80 kHz; amplitude¼ 6.5 kAm1), giving
nanocarriers with amaximum self-heating temperature reached
within 6–10 min of 44.5 C, 42.9 C and 40.5 C, respectively.
Therefore, by choosing a loading percentage of 8%, magnetic
polymeric NPs with a maximum self-heating temperature of
42.9 C and a LCST of 40.1 C are obtained. This is a very
interesting property, because as discussed previously, the
thermal enhancement of the cytotoxic activity of many anti-This journal is © The Royal Society of Chemistry 2014cancer agents is maximized at temperatures between 40.5 and
43 C. A maximum self-heating temperature close to 43 C
enables to stay in the mild hyperthermia temperature range to
fully benet the synergistic eﬀect of simultaneous hyperthermia
and chemotherapy.
Hydrogels consist of a three-dimensional polymer network
containing large quantities of water, but remain insoluble due
to their cross-linked structure. The properties of a hydrogel
such as its elasticity, degradation rate or swelling ratio can be
tuned bymodifying the hydrogel parameters (i.e. polymer, block
lengths, cross-linker ratio, etc.). Nanohydrogels are used as drug
delivery systems. Drugs are entrapped in the polymer matrix,
and released via diﬀusion or matrix degradation. MNPs can also
be incorporated into the hydrogel matrix.
Thermo-sensitive nanohydrogels are formed by cross-linking
thermo-sensitive polymers, and the nal LCST of the nano-
hydrogel can be tuned by changing the polymer ratio. Above the
LCST, the nanohydrogel becomes hydrophobic and shrink,
therefore expulsing water molecules and drugs.
A concentric layered magnetic chitosan hydrogel with
controlled layer numbers and layer thicknesses was recently
synthesised via a facile alternate alkali treatment method.167
Magnetite NPs and the chemotherapeutic drug adriamycin were
incorporated into the hydrogel matrix. The drug release
behaviour was estimated by switching ON and OFF a low
frequency alternating magnetic eld (LAMF). An increased rate
of drug release is observed when the LAMF is ON. In this study,
magnetic hyperthermia is not believed to be the trigger of the
drug release, but rather volume shrinkage of the hydrogel due to
the magnetisation of the MNPs, which promote drug release by
expelling the drug out of the hydrogel.
Jaiswal et al. developed dual pH and temperature stimuli-
responsive nanohydrogels by incorporating magnetite NPs into
a polymeric matrix based on poly(N-isopropylacrylamide)–chi-
tosan, with a LCST optimised around 42 C.168 DOX was used as
a chemotherapeutic drug and the pH and temperature
enhanced release was observed in an acid environment (pH 4.6)
and hyperthermia temperature (42 C). The cell killing eﬀect of
the drug loaded magnetic nanohydrogels was assessed on MCF-
7 cells (human breast cell line) and HeLa cells (cervical carci-
noma cell line). The combined treatment yielded up to 85% cell
death, which was signicantly higher than the cell death eﬃ-
cacy achieved by hyperthermia alone.
3.3.4 Core/shell nanoparticles. Core/shell NPs are particu-
larly relevant for combined modalities of cancer therapy.
Indeed, a metallic core can endow the NPs with the desired
magnetic properties for hyperthermia applications, while an
organic shell can provide drug loading capability. Moreover, the
coating can also provide increased colloidal stability (prevents
anisotropic magnetic dipolar attractions between MNPs),
chemical stability (i.e. prevents any further oxidation),
biocompatibility and reduce toxicity. The polymer can be graf-
ted onto the MNP surface (functionalising the MNPs by cova-
lently binding the polymer) by two diﬀerent approaches.169 In
the rst one, called “graing to or graing onto”, an end-
functionalised polymer is used with suitable terminal groups to
directly bind to the MNP surface. The second one, calledNanoscale, 2014, 6, 11553–11573 | 11565
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View Article Online“graing from”, the polymerisation proceeds from the surface
thanks to an initiator molecule preliminary xed on the MNP
surface. Finally, simpler but less reliable, the polymer can be
attached to the MNP surface by non-covalent interactions, such
as electrostatic or van der Waals interactions. There are two
major types of core/shell NP delivery system: the drug is phys-
ically loaded into the polymer shell and the drug is covalently
bonded to the polymer/ligand forming the shell of the MNPs. In
the latter, the drug release mechanism oen involves heat
inducing bond cleavage. In either case, it has been demon-
strated in vitro that DOX has higher cytotoxicity toward cancer
cells when it is conjugated to iron oxide NPs covalently or
electrostatically compared to free DOX, most likely due to
higher cellular uptake through endocytosis compared to passive
diﬀusion.170
3.3.4.1 Physical drug loading. Physical drug loading in the
polymer shell of the MNPs is generally obtained by hydro-
phobic/electrostatic interactions and is generally quite simple
to realise. For eﬃcient nanovectors, a high drug loading eﬃ-
ciency and rapid “on demand” release are desirable while drug
leakage through the polymer layer should be avoided. A recent
study has shown promising results with a pH-responsive system
in the drug release behaviour and cell killing eﬀect with the
combined therapy in the treatment of ovarian cancer.171 Iron
oxide NPs (28.5 nm) were synthesised and coated with three
diﬀerent layers, forming a reservoir for drug loading ability:
oleic acid, poly(maleic anhydride-alt-1-octadecene) (PMAO) and
poly(ethylene-imine) (PEI). DOX was then encapsulated into the
MNP polymeric shell and the MNPs were further modied with
a polyethylene glycol (PEG) layer for improved colloidal stability
and increased blood circulation time. Finally, the MNPs were
functionalised with a targeting ligand to human ovarian cancer
cells: Luteinizing Hormone–Releasing Hormone (LHRH)
peptide. This system will be called LHRH-PEG-DOX-IONPs (97.1
nm). The nanoformulation is pH-sensitive, and therefore the
drug release behaviour was evaluated at pH 5.5 (pH found in
tumour) and pH 7.4 (physiological pH). At pH¼ 7.4, only 17.6%
of the loaded DOX were released aer 72 h of incubation.
However, at pH 5.5, 91.1% of the loaded DOXwere released aer
72 h of incubation, with burst release within the rst 2 h
(44.7%). Indeed, DOX is loaded through electrostatic interac-
tions with the negatively charged carboxyl groups of the
amphiphilic polymer. The release of DOX is accelerated at
acidic pH because it reduces the interaction with protonated
carboxylic groups. It also increases the solubility of DOX in
aqueous solution due to the protonation of the primary amine
of DOX molecules. This drug release behaviour enables limited
release of the drug into the blood stream, while quick release
can be obtained at cancer sites. The hyperthermia potential of
the DOX free system was evaluated in vitro on an A2780/AD
human ovarian carcinoma cell line, with an iron concentration
of 15 mg mL1. The experiments were carried out at two
temperatures, 40 C and 44 C, with an AMF of constant
frequency (393 kHz) and the magnetic eld amplitude set at
33.5 kA m1 (for 44 C) and 21.2 kA m1 (for 40 C), and an
exposure time of 30 min. The experiments resulted in 95% and
72% cell death for hyperthermia at 44 C and 40 C, respectively.11566 | Nanoscale, 2014, 6, 11553–11573Thus, hyperthermia at 44 C has a direct cell killing eﬀect. In
order to assess the eﬃcacy of the combined treatment, 15 mg Fe/
mL of LHRH-PEG-DOX-IONPs were loaded with 1 mg mL1 of
DOX and subjected to an AMF under mild hyperthermia
conditions (40 C). The eﬀect of DOX alone resulted in a cell
viability decrease by 70% while the combined treatment had a
95% cell killing eﬀect. Thus, the combined treatment shows a
superior eﬃcacy to either chemotherapy or mild hyperthermia
as stand-alone therapy and is preferable in many ways because
of the lower temperature and drug concentration used, thereby
minimizing side eﬀects and damage to healthy tissues. Elec-
trostatic interactions were also used to load DOX into MgFe2O4
magnetic nanoassemblies coated with PEG–diacid.172 A loading
eﬃciency of 80%was achieved and 75–80% of DOX was released
under acidic pH (5.4) compared to only 20–25% at physiological
pH (7.4), within 24 h. The synergistic eﬀect of DOX combined
with hyperthermia was once more observed, with up to 90% cell
death (against 45% and 65% cell death for magnetic hyper-
thermia alone and chemotherapy alone, respectively).
Barick et al. developed pH-responsive peptide mimic shell
cross-linked magnetic nanocarriers (PMNCs) for combination
therapy.173 Magnetite NPs (10 nm) were functionalised with
glycine and the free amine groups are utilised for further
conjugation with the peptide L-arginine to obtain PMNCs with
both amine and carboxylic terminal groups (50 nm). The NPs
were coated with a peptide, because peptides can enhance the
cellular uptake, have low toxicity and are pH-responsive. The pH
of zero point charge of PMNCs was estimated to be 5.4, meaning
that the surface is charged positively at pH < 5.4 and negatively
at pH > 5.4. The reversal of the surface charge can be exploited
for the purpose of drug delivery: the drug, loaded in the shell, is
retained via electrostatic interactions, and released upon the
change of surface charge. DOX is used as a model of cationic
chemotherapeutic agents to study the drug loading and release
behaviour at pH 4, 5 and 7.3. They observed that the loading
eﬃciency was strongly dependent on the ratio of PMNCs to DOX
and achieved a maximum DOX loading eﬃciency of 80% at
PMNCs to DOX ratio of 10. The DOX release studies show an
increase in the release rate with a decreasing pH: only 7% of
DOX was released at pH 7.3 while the release was complete at
pH 4. The time needed for the release of 50% of DOX was found
to be around 30 min and 45 min at pH 4 and 5, respectively. The
potential of the DOX loaded PMNCs was investigated on HeLa
cells for the combined therapy, aer only 10 min of AMF
exposure (frequency¼ 265 kHz; amplitude¼ 335 Oe) and a DOX
concentration of 4 mM. The chemotherapy treatment alone (free
DOX or DOX-loaded PMNCS) resulted in a cell viability decrease
by 10%, and hyperthermia alone (PMNCs subjected to AMF)
had a 13% decreased eﬀect on the cell viability. The cell killing
eﬀect was higher in the case of the combined therapy, as a 28%
decrease in cell viability was observed. This system is interesting
for the combined therapy giving the results obtained with a
short time of AMF exposure and low DOX concentration.
Moreover, it exhibits quasi-inexistent drug leakage through the
peptide mimic shell and the amine and carboxylic terminal
groups of the nanocarriers gives a lot of possibility for the
conjugation of targeting ligands.This journal is © The Royal Society of Chemistry 2014
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View Article OnlineWhile being eﬃcient, the use of pH-sensitive drug delivery
systems does not allow the remote control of the drug release.
Thermo-sensitive drug delivery vehicles can be used for hyper-
thermia-triggered drug release which oﬀer spatial and temporal
control over the drug release but also oﬀer the possibility of
“ON–OFF” release by switching ON and OFF the AMF. For
example, magnetite NPs coated with N-isopropylacrylamide-co-
acrylamide (P(NIPAAm-co-Am)) with a LCST of about 40 C show
almost complete drug release aer three AMF ON–OFF cycles
(frequency ¼ 60 kHz; amplitude ¼ 6.5 kA m1).174
3.3.4.2 Covalent drug loading. The advantage of the conju-
gated drugs to the MNP surface via a labile bond is that no
leakage of the drug through the polymer shell is possible. This
design involves the cleavage of the bond used to conjugate the
drug to the MNP in response to a stimulus. The drug can
therefore be magnetically guided at the right location and
activated at the right time, limiting systematic eﬀects to a great
extent. For the purpose of thermo-chemotherapy, heat labile
bonds are particularly relevant, because the heat produced by
the MNPs subjected to an AMF would induce the bond cleavage.
For example, in the following study, the authors have designed a
magnetic nanocarrier for thermo-chemotherapy composed of
an iron oxide core functionalised with a ligand allowing the
release of the drug through a combination of click reactions.175
The ligand contains a phosphonic acid group which gives
strong binding to the NPs, and an alkyne group which allows a
copper catalyzed 1,3-dipolar cycloaddition (CuAAC) with
an azide. This reaction is used to link an azide terminated
poly(ethylene oxide) monomethyl ether which provides
biocompatibility, stability and antifouling properties to the NPs.
The ligand also contains a furan ring making possible a Diels–
Alder (DA) reaction used to link a drug. In this study, a dye
(tetramethylrhodamine-5-C2-maleimide (Rhd-M)) was used to
investigate the potential of the nanosystem for drug delivery.
The DA reaction occurs between an alkene and a diene and is
thermoreversible. Therefore, the biologically active molecule
can be released by provoking the retro-DA (rDA) reaction. The
rDA reaction generally occurs at temperatures around 90–110
C. Even though those temperatures can seem really high for
biological purposes, recent studies have shown the existence of
local heating eﬀects in the vicinity of MNPs leading to high
temperatures at the NP surface.176,177 This phenomenon can be
exploited to kill more eﬀectively cancer cells without a signi-
cant increase of temperature in the biological medium, or in the
case of this study, trigger the drug release by initiating the rDA
reaction. Indeed, the ligand has been designed to provide the
cleavable bond close to the NP surface, allowing the exploitation
of the local heating phenomenon. The study shows that, indeed,
upon application of an AMF, the rDA reaction occurs, leading to
the release of the dye Rhd-M, and thereby this design oﬀers
possibility for thermo-chemotherapy applications.
Even if heat labile bonds are particularly convenient for
hyperthermia with combined chemotherapy, acid labile bonds
are also widely used for drug delivery applications, as the pH in
the tumour environment is more acidic than in blood or healthy
tissue. A recent study used an acid labile imine bond to
conjugate doxorubicin to magnetite NPs.178 The mechanism byThis journal is © The Royal Society of Chemistry 2014which the drug is released was assumed as follows: the MNPs
are taken up by endocytosis by the cancer cells, and the drug is
released in acid lysosomes due to the bond cleavage in acidic
conditions (pH in lysosomes is between 3.5 and 5). Other acid
cleavable bonds have been used recently for drug delivery
purposes and could be used for the combined therapy, such as
hydrazone bonds to conjugate DOX to magnetite NPs179,180 or
nanocrystal clusters181 or else ester bonds to conjugate pacli-
taxel to iron oxide NPs.182
Finally, other possible cleavable bonds that can be used for
drug delivery are redox labile bonds such as disulde bonds.183
Indeed, the reductive tumour intracellular environment due to
the elevated level of reductive glutathione in many tumour cells
enables redox bond cleavage thus releasing the drug. Acid and
redox cleavable bonds for use in drug delivery applications have
another important advantage. Indeed, it has been noticed that a
high amount of glutathione is oen associated with chemo-
therapeutic drug-resistant cancer.184 However, by releasing
drugs intracellularly (as in the case of drugs conjugated by pH
or redox cleavable bonds), drug resistance can be overcome.185
If the drug used also have a targeting ability, no cleavage of
the bond conjugating the drug molecules to the MNPs is
necessary. This is the case of the drug methotrexate which has
been used in a recent study for thermo-chemotherapy.186
Magnetite NPs were prepared by the co-precipitation method
and coated with poly(ethyleneimine) (PEI). PEI is used to
improve colloidal stability, and to conjugate methotrexate
(MTX) through an amide bond. MTX is used for its targeting
ability on the folate receptor (over-expressed in many types of
cancers) and its therapeutic eﬀect. MCF-7 cells (positive to
reduced folate carriers) were used for the in vitro studies and
L929 cells as control. The cellular uptake shows a more eﬃcient
and selective internalisation in the cell cytoplasm of MTX-MNPs
compared to non-conjugated MNPs. The relative cell viability
was estimated for MNP hyperthermia or chemotherapy alone
(MTX-MNPs without application of a magnetic eld) and the
combined treatment. 200 mL of MTX-MNPs with a MNP and
MTX concentration of 25 mg mL1 and 100 mM, respectively,
were used for the measurement, at a temperature of 43 C for 20
min (magnetic eld frequency: 300 kHz; and maintaining the
temperature by adjusting the amplitude of the magnetic eld).
The cell viabilities for the MNPs alone, MTX-MNPs without
application of a magnetic eld and MTX-MNPs with application
of a magnetic eld were decreased to 87.6 10.8%, 64.5 7.2%
and 13.3  1.3%, respectively. A true synergistic eﬀect between
hyperthermia and MTX is thus observed, demonstrating the
eﬃciency of the MTX-MNP design.3.4 Examples of in vivo applications of thermo-
chemotherapy
To the best of our knowledge, there has been no clinical trial
performed on drug-loaded MNP-based nano-systems for
simultaneous thermo-chemotherapy. However, the fate and
eﬀectiveness of diﬀerent magnetic carriers have been tested in
vivo. In vivo experiments are important because the overall
eﬀects can be observed on a living subject and it is therefore theNanoscale, 2014, 6, 11553–11573 | 11567
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View Article Onlinebest way to get close from the conditions found in a human
body (pH, complicated tumour microenvironment, etc.) which
can interfere to a great extent with the fate of the nano-systems
(i.e. drug pharmacokinetic, NP distribution pattern, etc.). Yoo
et al. introduced resistance-free apoptosis-inducing magnetic
nanoparticles (RAIN) based on Zn0.4Fe2.6O4 MNPs for simulta-
neous hyperthermia therapy and release of geldanamycin
(GM).187 GM is a heat shock protein (HSP) inhibitor and is used
to prevent thermo-resistance. Indeed, consecutive hyper-
thermia treatment oen results in the development of resis-
tance to the cytotoxic eﬀect of heat.188 This phenomenon is
called thermoresistance and arises from the synthesis of HSPs
as a response of thermal stress. Indeed, the presence of HSPs
has been correlated with the natural adaptation to heat of a
living organism. GM is conjugated to the MNPs via a heat labile
azo linker, and complete release occurs as a consequence of
magnetic hyperthermia aer 60 min of exposure at 43 C with
an applied eld of frequency ¼ 500 kHz and amplitude ¼ 37.4
kA m1. No release is observed at 37 C. The in vitro studies on
MDA-MB-231 breast cancer cells revealed a 100% cell killing
eﬃciency aer 70 min of treatment (43 C) with the RAIN,
against only 25% aer 80 min of treatment for magnetic
hyperthermia alone. A strong expression of HSPs was observed
aer the hyperthermic treatment, while aer exposure to RAIN
hyperthermia, the expression of HSP was comparable to the
control. Finally, MDA-MB-231 cells were transplanted into the
right hind legs of nude mice and 50 mg of RAIN were directly
injected into the tumour. Hyperthermia at 43 C was main-
tained for 30 min. Magnetic hyperthermia was not suﬃcient to
inhibit the tumour growth, but RAIN hyperthermia was found
to completely suppress the tumour 8 d aer single AMF expo-
sure. The in vitro and in vivo tests conrmed that HSPs are
responsible for the thermo-resistance phenomenon and that its
inhibition is critical for hyperthermia induced apoptosis.
Li et al. developed truncated octahedral magnetite NPs (edge
length: 22 nm) coated with poly(styrene-alt-maleic acid) (PSMA)
and further functionalised with PEG and poly-A poly-
nucleotide.189 PEG chains are used to increase the blood circu-
lation time and to bind a cancer cell targeting moiety: the anti-
human epidermal growth factor receptor type 2 (anti-HER2)
monoclonal antibody, while the polynucleotide has the ability
to absorb the chemotherapeutic drug 5-uorouracil (5-FU) by
forming a hydrogen bond between the adenine group of the
polynucleotide and 5-FU (5-FU loaded Fe3O4@anti-HER2). They
demonstrated the superiority of the targeted nano-system in
vitro on MBT-2 cells, a mouse bladder cancer cell line which
over-expresses HER2 antigen, compared to the non-targeted one
(triple the number of NPs targeting MBT-2 cells and enhance
cellular uptake). MBT-2 cells were transplanted into C3H/HeN
mice to induce bladder cancer in mice for in vivo experiments.
Firstly, 50 mL of a solution of 5-FU loaded Fe3O4@anti-HER2
NPs were injected intratumourally to assess the eﬃcacy of the
combined therapy on small size (<50 mm3) and large size (>50
mm3) tumours. The tumours were exposed to an AMF for 15
min (frequency: 1.3 MHz; amplitude: 33 kAm1) 2 h later. In the
case of small tumours, hyperthermia alone as well as the
combined treatment led to almost total tumour regression.11568 | Nanoscale, 2014, 6, 11553–11573However, for large tumours, hyperthermia alone was not suﬃ-
cient enough to signicantly inhibit tumour growth, and only
hyperthermia with combined chemotherapy resulted in a
signicant anti-cancer eﬀect. Secondly, the eﬃcacy of the
combined treatment was evaluated using the systematic
delivery method through tail-vein injection. 200 mL of 5-FU
loaded Fe3O4@anti-HER2 NPs with a concentration of 500 mg
mL1 were injected once per day for four consecutive days and
the hyperthermia treatment was applied 24 h aer the NPs had
been injected. The combined treatment resulted in a prominent
cancer regression compared to either hyperthermia or 5-FU
alone. Interestingly, vital organs showed no detectable patho-
logical ndings 48 h aer tail-vein injection while higher
accumulation of 5-FU loaded Fe3O4@anti-HER2 in tumours was
detected 48 h rather than 24 h post-injection. Moreover, aer
hyperthermia treatment, relocation of the NPs from other
organs to the tumour was observed, probably due to the change
in tumour vasculature in response to hyperthermia which
facilitates NP extravasation. This information is highly valuable
in maximizing the therapeutic eﬀect and minimizing the side
eﬀects of the treatment. It also suggests that pre-hyperthermia
treatment could be applied before injection of the NPs to
increase their accumulation at the cancer site.
Wang et al. evaluated the therapeutic eﬃcacy ofMn0.5Zn0.5Fe2O4
(MZF) NPs and arsenic trioxide (As2O3) encapsulated in thermo-
sensitive magnetoliposomes (TSMLs) composed of 1,2-dipalmitoyl-
sn-glycero-3-phosphocholine (DPPC), cholesterol and vitamin E
(54 : 6 : 1, m/m) (128.2 nm) in rabbits with a 2.0 cm diameter VX2
tumour in the le liver lobe.190 As2O3 has a powerful antitumour
eﬀect onmalignant solid tumours and was used in this study as an
anti-cancer agent. The crystalline phase transition temperature of
the liposomewas estimated to be 42.7 C. The drug release between
37 C and 39 C was inexistent and very low at 40 C and 41 C.
Then, the release percentage jumped to 65.55% at 42 C, 78.66% at
43 C and nally reached 98.32% at 44 C. The liposomes were
injected into the tumour feeding artery. Hyperthermia treatment
was applied for 60 min with an AMF (frequency ¼ 230 kHz; I ¼ 30
A). The temperature reached 44 C within 30 min and remained
stable for the next 30 min, beneting from the self-heating control
behaviour of MZF NPs due to their low Curie temperature. The
combined treatment had the most eﬀective anti-cancer eﬀect, with
a cell growth inhibition rate of 85.22%, against 52.68% for lipo-
somes entrapping MZF and 44.96% for liposomes entrapping
As2O3.
4. Conclusions and perspectives
Water colloidal dispersion of MNPs has shown great potential
for use as heat-mediators agents, and eﬀorts in the eld have
led to promising preclinical and clinical studies. However, MFH
is still far from achieving its full clinical potential. Most of the
research on magnetic nanoparticle-mediated hyperthermia
therapy has been directed toward MNPs exhibiting good
biocompatibility and an improved SAR value. However, as the
SAR increases with increasing frequency and amplitude of the
applied eld, one needs to pay careful attention to these values.
Indeed, a too strong AMFmay generate eddy currents and causeThis journal is © The Royal Society of Chemistry 2014
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View Article Onlinenon-specic heating and therefore damaging of both healthy
and cancer tissues. Nonetheless, many of the research groups
used magnetic elds with an Hf factor exceeding the deter-
mined biologically safe threshold, which is unfortunate because
the heating potential could be in fact insuﬃcient for any
applications under clinical conditions. Indeed, the higher the
SAR, the lower is the MNP concentration needed to achieve the
temperature range for full therapeutic eﬃcacy, which is crucial
as a too high NP concentration may have signicant toxicity.
Magnetic hyperthermia combined with drug delivery does not
require temperatures as high as those used for hyperthermia
therapy alone. Indeed, as discussed previously, the thermal
enhancement of drug cytotoxicity is maximized at mild hyper-
thermia temperatures, meaning that the MNPs do not need to
possess such an exceptional SAR value for use in the combined
therapy. Moreover, it has been proven many times through in
vitro as well as in vivo studies that the combination therapy is far
more eﬀective than either hyperthermia or chemotherapy alone.
As the combination of hyperthermia and chemotherapy in a
sameMNP-based nano-therapeutic system is relatively new, there
are still some obstacles to tackle before clinical trials can be
carried out. A high drug loading should be achieved and drug
diﬀusion from the nanocarriers should be suppressed to limit
systematic delivery. The pharmacokinetic and pharmacodynamic
of the nanosystem needs to be studied for a better comprehen-
sion and a possible increase in the treatment eﬃcacy. However,
thermo-chemotherapy by means of a magnetic nano-system
gathers all the numerous advantages of MFH over traditional
hyperthermia and controlled drug release over traditional
chemotherapy. Better anti-cancer eﬀects at lower drug thera-
peutic dose and lower temperatures are achieved with the
combined therapy. The possibility of triggering the drug release
in cancer sites thanks to the use of pH- or thermo-sensitive-based
nanocarriers is a particularly attractive feature to control the
spatiotemporal release of the drug. The nano-systems can be
functionalised with an active targeting moiety to increase the
amount of particles delivered to the tumour site as well as the
cellular uptake. The use of MNPs also gives the opportunity to
target a site of interest via magnetic targeting. Finally, the eﬃ-
cient delivery of the nanoformulation combining MNPs and
drugs can be conrmed by MRI, as MNPs and especially iron
oxide NPs are eﬀective contrast agents.191–194 Undoubtedly, MNPs
havemany potential applications in biomedicine,195 among them
magnetic hyperthermia is perhaps the most exciting aspect and
has huge amount of attention and attracts a lot of research
activities. However, for this eld to progress, particular attention
must be paid to the synthesis and biofunctionalisation of NPs to
enhance their overall performance196,197 and move over under-
standing the mechanisms of nucleation and growth of NPs is
important to obtain control over the nanoparticle synthesis and
overcome current methods of trial and error.198Acknowledgements
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